Novo Nordisk is making progress toward stabilizing Wegovy supply

Danish pharmaceutical company Novo Nordisk is hard at work with stabilizing the supply of its obesity drug Wegovy, which has been in high demand in the US since its June launch.

Photo: Novo Nordisk / PR

Novo Nordisk is currently making progress in securing its supply of the obesity drug Wegovy, the company reports on its website.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs